Skip to main content

10-Year Outcomes of Initial CTO-PCI vs No CTO-PCI Strategies for Chronic Total Occlusion: The DECISION-CTO Randomized Trial

In brief

Opening chronic total occlusions showed no clear 10-year event advantage

In a randomized trial, the 10-year composite of death, heart attack, stroke or repeat revascularization occurred in 33.9% of patients assigned to artery-opening PCI and 37.4% assigned to no CTO-PCI, a difference that was not statistically significant. Death rates also did not differ significantly; wide uncertainty means the trial cannot rule out meaningful benefit or harm.

Journal
Journal of the American College of Cardiology (Q1)
Published
2 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Ju Hyeon Kim, Do-Yoon Kang, Jung-Min Ahn, Seong-Bong Wee, Sehee Kim, Hyuck-Jun Yoon, et al.
PMID
43037535
DOI
10.1016/j.jacc.2026.10.068

Why clinicians should know about it

Abstract

BACKGROUND: The long-term clinical effects of percutaneous coronary intervention for chronic total occlusion (CTO-PCI) remain uncertain. OBJECTIVES: This study aimed to compare 10-year clinical outcomes between initial CTO-PCI and no CTO-PCI strategies in the extended follow-up of the DECISION-CTO trial. METHODS: The DECISION-CTO trial was an open-label, multicenter, randomized trial conducted at 19 centers in 5 Asian countries. Patients were randomly assigned to an initial strategy of CTO-PCI or no CTO-PCI, with guideline-directed medical therapy in both groups and PCI of obstructive non-CTO lesions encouraged in both groups. The primary endpoint was a composite of death from any cause, myocardial infarction, stroke, or any revascularization at 10 years, analyzed in the modified intention-to-treat group. RESULTS: Between March 2010 and October 2016, 834 patients were randomly assigned, and 804 of these patients were included in the modified intention-to-treat analysis (413 CTO-PCI, 391 no CTO-PCI). Clinical follow-up at 10 years was complete in 688 patients (85.6%), without a significant between-group difference (P = 0.69). At 10 years, the primary endpoint had occurred in 134 patients in the CTO-PCI group and 138 patients in the no CTO-PCI group (Kaplan-Meier estimates: 33.9% vs 37.4%; risk difference: -3.5 percentage points; 95% CI: -10.4 to 3.3 percentage points; P = 0.32). Restricted mean event-free survival time at 10 years was also similar between groups (7.52 vs 7.53 years; difference: -0.01 years; 95% CI: -0.54 to 0.52 years; P = 0.97). Death from any cause did not differ significantly between groups (12.7% vs 16.5%; HR: 0.76; 95% CI: 0.52-1.12; P = 0.16). CONCLUSIONS: Over 10 years, an initial strategy of CTO-PCI was not associated with a significant difference in the primary endpoint or all-cause mortality compared with an initial strategy of no CTO-PCI. However, the wide CIs preclude definitive conclusions regarding the potential benefit or harm of an initial CTO-PCI strategy. (Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion [DECISION-CTO]; NCT01078051; extended follow-up, NCT06908499).

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.